An overview of the retinoids

The American Journal of Medicine

Volumn 86, Issue 5 C, 1989, Pages 568-574

  Boyd, Alan S ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1 PROPENYL]BENZOIC ACID; 4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1 PROPENYL]BENZOIC ACID ETHYL ESTER; AROTINOID; ETRETIN; ETRETINATE; ISOTRETINOIN; RETINOIC ACID; RETINOID; RETINOL;

ACNE; CHEILITIS; DERMATITIS; DRUG METABOLISM; EPISTAXIS; HUMAN; HYPEROSTOSIS; HYPERTRIGLYCERIDEMIA; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN CANCER; TERATOGENICITY; THERAPY; TOPICAL DRUG ADMINISTRATION;

ABNORMALITIES, DRUG-INDUCED; ETRETINATE; FEMALE; HUMAN; ISOTRETINOIN; PREGNANCY; RETINOIDS; SKIN DISEASES; SUPPORT, NON-U.S. GOV'T; TRETINOIN;

EID: 0024536824     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(89)90386-0     Document Type: Review

References (93)

1. Vitamin A
2. Treatment of acne vulgaris and senile keratoses with vitamin A
3. Historical perspectives of tretinoin
4. Topical vitamin A acid in acne vulgaris
5. Vitamin-A-saüre bei hyperkeratosen epithelialen tumoren und akne
6. The development of retinoids in experimental and clinical oncology and dermatology
7. The development of retinoids in dermatology
8. Efficacy of topical isotretinoin 005% gel in acne vulgaris results of a multicenter double-blind investigation
9. Oral retinoids—present status
10. Acitretin versus etretinate in psoriasis
11. Retinoids: a review
12. Hypervitaminosis A syndrome: a paradigm of retinoid side effects
13. Vitamin A concentration in human tissues collected in five areas in the United States
14. All-trans-retinoic acid: measurement of reference values in human seram by high performance liquid chromatography
15. Retinoids and acne
16. Clinical pharmacokinetics of the retinoids
17. Retinoid concentrationns in skin, serum and adipose tissue of patients treated with etretinate
18. Etretinate: a review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders
19. Etretinate persistent serum levels of a potent teratogen
20. New indications and new retinoids
21. Etretinate therapy
22. In vitro binding of retinol to rat tissue components
23. Cellular retinol-binding protein allows specific interaction of retinol with the nucleus in vitro
24. Presence of cellular retinol and retinoic acid-binding proteins in experimental tumors
25. How do retinoids work?
26. Etretinate treatment for psoriasis inhibits epiderman orinthine decarboxylase
27. Evidence for anti-inflammatory activities of oral synthetic retinoids: experimental findings and clinical experience
28. Anti-inflammatory effects of 13-cis-retinoic acid
29. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin
30. Mucocutaneous and systemic toxicity of retinoids: monitoring and management
31. Effects of retinoids in bone
32. Toxicology, carcinogencity and teratogenicity of some orally administered retinoids
33. Retinoic acid embryopathy
34. Lipid and teratogenic effects of retinoids
35. Isotretinoin and teratogenicity
36. Topical tretinoin for hair growth production
37. Topical tretinoin for photoaged skin
38. Topical tretinoin improves photoaged skin: a double-blind vehicle-controlled study
39. Effects of all-trans-retinoic acid on the dermis of hairless mice
40. Topical tretinoin in the treatment of aging skin
41. Treatment of solar keratoses of extremities with retinoic acid and 5-fluorouracil
42. Treatment of lamellar ichthyosis and other keratinizing dermatoses with an oral synthetic retinoid
43. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid
44. The effect of marked inhibition of sebum production with 13-cis-retinoic acid on skin surface lipid composition
45. Qualitative and quantitative changes in cutaneous bacteria associated with systemic isotretinoin therapy for acne conglobata
46. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin)
47. Action of isotretinoin in acne, rosacea, and gram-negative folliculitis
48. Topical application of isotretinoin gel improves oral lichen planus
49. Treatment of cutaneous sarcoidosis with isotretinoin
50. Treatment of basal cell carcinomas with 13-cis-retinoic acid
51. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid
52. Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations
53. General clinical toxicology of oral retinoids
54. Isotretinoin treatment of acne and related disorders: an update
55. Adverse reactions to isotretinoin
56. Elevation of serum triglyceride levels from oral isotretinoin in disorders of keratinization
57. Retinoid toxicity: lipids
58. Retinoid hyperostosis
59. Long-term radiographic follow-up after isotretinoin therapy
60. Premature epiphyseal closurer in a child receiving oral 13-cis-retinoic acid
61. Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro 10-9359)
62. Etretinate in severe psoriasis
63. Etretinate in pustular psoriasis of palms and soles
64. Etretinate therapy for psoriasis
65. Treatment of psoriasis by oral PUVA therapy combined with aromatic retinoid (Ro 10-9359; Tigason)
66. Oral retinoid and UVB radiation: a new alternative treatment for psoriasis on an out-patient basis
67. Etretinate and betamethasone valerate in the treatment of psoriasis
68. Treatment of generalized pustular psoriasis with etretinate (Ro 10-9359) and methotrexate
69. Le rétinoide aromatique assorié a la photochimiothérapie pour le traitment du psoriasis et du rhumatisme psoriasique
70. Therapeutic evaluation of the oral retinoid Ro 10-9359 in several nonpsoriatic dermatoses
71. Severe disorders of keratinization: effects of treatment with Tigason (etretinate)
72. Oral retinoid (Ro 10-9359) in children with lamellar ichthyosis, epidermolytic hyperkeratosis and symmetrical progressive erythrokeratodermia
73. Degree of bronchial metaplasia in heavy smokers and its regression after treatment with a retinoid
74. Treatment of cutaneous lymphoma with etretinate
75. Etretinate in treatment of actinic keratoses
76. Treatment of arsenical keratosis with etretinate
77. Aromatic retinoid in the chemoprevention of the progression of nevoid basal-cell carcinoma syndrome
78. Effects of retinoid (Ro 10-9359) on the plasma membrane of keratinocytes in patients with psoriasis: a freeze-fracture analysis
79. The effect of etretinate on the cyclooxygenase and lipoxygenase products of arachidonic acid metabolism in psoriatic skin
80. Leukotrienes and other lipoxygenase products in the pathogenesis and therapy of psoriasis and other dermatoses
81. Etretinate therapy reduces polymorphonuclear leukocyte chemotaxis-enhancing properties of psoriatic serum
82. Etretinate therapy and immune acitivites
83. The role of neutrophil leukocytes in the psoriatic epidermal process: preliminary results
84. Inhibition of neutrophil migration by etretinate and its main metabolite
85. Fish oil consumption reduces hypertriglyceridemia in psoriatic patients receiving etretinate therapy
86. Etretinate appropriate use in severe psoriasis
87. Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate
88. Lack of skeletal radiographic changes during short-term etretinate for psoriasis
89. Electromyographic abnormalities in patients undergoing long-term therapy with etretinate
90. Etretinate (Tigason, Europe; Tegison, USA) in psoriasis: advantage of low doses progressively increased (letter)
91. Systemic retinoid therapy for psoriasis
92. Antipsoriatic activity of a new synthetic retinoid: the arotinoid Ro 13-6298
93. Topical and systemic effects of three retinoids on androgen receptors and size of sebaceous glands (ear and flank organ) in syrian hamsters